As mentioned above, the first in vivo imaging of AD hallmark pathology was initially developed and tested in transgenic murine models of AD by Koronyo-Hamaoui and colleagues (Koronyo-Hamaoui et al., 2011; Koronyo et al., 2012). The researchers paired curcumin – a natural and safe fluorochrome that labels Aβ fibrils and oligomers with high affinity and specificity – with a modified rodent retinal optical imaging microscope. Later, this approach was translated to humans and the feasibility to noninvasively detect and quantify individual retinal amyloid plaques was demonstrated in living patients with a modified confocal scanning laser ophthalmoscope following oral administration of highly bioavailable Longvida curcumin (Figures 7A–D; Garcia-Alloza et al., 2007; Gota et al., 2010; Koronyo-Hamaoui et al., 2011; Koronyo et al., 2012, 2017). Studies in murine ADtg models demonstrated the feasibility to longitudinally monitor individual Aβ deposits including their appearance and clearance during disease progression and in response to immune-based therapy (Koronyo et al., 2012).